Core Insights - Certara, Inc. has published over 200 papers in the past year and has 11 scientists listed among the top 2% most cited researchers globally according to the 2025 Stanford/Elsevier ranking, highlighting its significant impact in pharmaceutical research [1][2][3] Company Achievements - The company has maintained its leadership in pharmacology and pharmacokinetics, with its scientists recognized for their contributions either in the calendar year 2024 or throughout their careers [3] - Amin Rostami-Hodjegan, a key figure at Certara, received the 2025 Lewis B. Sheiner Lecturer Award for his lifetime achievements in pharmacometric research [4] Technological Innovations - The Simcyp Simulator®, co-founded by Rostami-Hodjegan, is utilized by over 11 global regulatory agencies and has supported more than 120 FDA-approved drugs, demonstrating its effectiveness in drug development [4] - The Simcyp Consortium, consisting of 35 leading biopharmaceutical companies, is recognized as a global authority on mechanistic PBPK modeling and simulation [4] Industry Trends - New methodologies like the Simcyp Simulator are crucial as the biopharma industry shifts away from animal testing, a transition supported by the FDA and NIH [5] - Certara has been at the forefront of reducing animal use in pre-clinical research for the past 25 years, aligning with industry trends towards more ethical research practices [5]

Core Viewpoint - Cerrado Gold Inc. reported a 21% increase in gold equivalent ounce (GEO) production for Q3 2025 compared to the previous quarter, driven by enhanced operations at the Calandrias Sur heap leach site and ongoing underground development at the Minera Don Nicolas Mine [3][9]. Q3 Operating Highlights - Q3 2025 production reached 13,868 GEO, up from 11,437 GEO in Q2 2025, marking a 21% increase [9]. - Heap leach production grew by 33% to a record 10,465 GEO due to expanded crushing capacity and improved recoveries [9]. - The completion of the second phase of the crushing expansion led to improved tonnage and recoveries [3]. - The underground development is progressing, with three access portals developed, expected to reach production stopes in Q4 2025 [5][9]. - The company revised its 2025 production guidance from 55,000-60,000 GEO to 50,000-55,000 GEO due to delays in underground development [6][8]. Exploration and Development Updates - The exploration program at Minera Don Nicolas is expanding, with an additional 50,000 meters planned for 2026, supplementing the existing 20,000 meters for 2025 [8][12]. - Promising results have been observed in the central Paloma area, indicating potential resource expansion [12]. - Development activities are ongoing at the Lagoa Salgada and Mont Sorcier projects, with feasibility studies targeted for completion in Q4 2025 and Q2 2026, respectively [14][15]. Corporate Activities - Joao Barros has been appointed as President, Europe, and Carl Calandra as Corporate Secretary [20]. - The company engaged Hybrid Financial Ltd. for strategic marketing and investor relations services to enhance its investor profile [21]. - Cerrado issued 200,000 deferred share units and 20,000 restricted share units under its incentive plan [22]. Financial Performance - The average realized price per gold ounce sold increased to $3,153 in Q3 2025 [18]. - The company continues to optimize operations at its Minera Don Nicolas and Las Calandrias projects, aiming to maximize asset value [24][25].

Core Insights - Chris Lau is an experienced investor and economist with 30 years in life science, technology, and dividend-growth income stocks [1] - He operates the DIY Value Investing group, focusing on undervalued stocks with catalysts for potential upside and dividend-income recommendations [1] Group 1: Flagship Products - Top DIY Picks feature undervalued stocks with upcoming catalysts that the market does not expect [2] - Dividend-income Champs include stocks with a long history of dividend growth, along with a printable calendar and quantitative scores [2] - DIY Community Picks are aimed at speculative allocations with positive momentum [2]

Group 1 - Chris Lau is an experienced investor and economist with 30 years in life science, technology, and dividend-growth income stocks [1] - He holds degrees in Microbiology and Economics, enhancing his analytical capabilities in investment [1] - Lau operates the DIY Value Investing group, focusing on undervalued stocks with catalysts for potential upside and dividend-income recommendations [1] Group 2 - The flagship products include Top DIY Picks, which are undervalued stocks with upcoming catalysts that the market does not expect [2] - Dividend-income Champs feature stocks with a long history of dividend growth, accompanied by a printable calendar and quantitative scores [2] - DIY Community Picks are aimed at speculative allocations with positive momentum [2]

Core Viewpoint - Cerrado Gold Inc. announces the resignation of Mr. Robert Campbell from its board of directors as he intends to retire, with management expressing gratitude for his contributions and wishing him well in retirement [1] Group 1: Company Overview - Cerrado Gold is a Toronto-based gold production, development, and exploration company, fully owning the Minera Don Nicolás and Las Calandrias mines in Argentina [2] - The company holds an 80% interest in the Lagoa Salgada VMS project in Portugal and is developing the Mont Sorcier Iron project in Canada, which it fully owns [2] Group 2: Operations in Argentina - In Argentina, Cerrado is enhancing asset value at the Minera Don Nicolás operation through operational optimization and increasing production at the Las Calandrias heap leach project [3] - An extensive exploration campaign is ongoing to unlock potential resources in the Deseado Masiff region [3] Group 3: Operations in Portugal - In Portugal, Cerrado is focused on the Lagoa Salgada VMS project, which is located on the Iberian Pyrite Belt and is characterized by high-grade polymetallic mineralization including zinc, copper, lead, tin, silver, and gold [4] - The project has significant exploration potential across its 7,209-hectare property and is strategically located 80 km from Lisbon, benefiting from excellent infrastructure [4] Group 4: Operations in Canada - Cerrado's Mont Sorcier Iron project has the potential to produce premium iron concentrate with low operating costs and a long mine life [5] - The high-grade and high-purity product supports the transition of steel producers to electric arc furnaces, aiding in the decarbonization of the industry [5]

Core Viewpoint - Certara, Inc. will release its financial results for Q3 2025 on November 6, 2025, after market close, followed by a conference call to discuss the results [1]. Company Overview - Certara is a global leader in biosimulation, utilizing software, technology, and services to enhance drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Event Details - A conference call will be held at 5:00 PM ET on the same day as the financial results release, and investors must register online to participate [1]. - It is recommended that investors register at least one day in advance [1]. - A live and archived webcast of the event will be available on Certara's website [2].

Core Insights - Cerrado Gold Inc. is accelerating its exploration program at the Minera Don Nicolas gold mine, increasing the scope from 20,000 metres to approximately 50,000 metres in 2026 by adding three additional drill rigs [1][2][4] Exploration and Development - The company plans to expedite assay completion by certifying its on-site lab, allowing for quicker turnaround times and issuing exploration results in batches for better clarity [2][4] - Operations at the Minera Don Nicolas site are performing well, with new investments in mining equipment leading to a delivery rate of 300,000 tonnes per month to the leach pad [3][4] - Underground development is progressing, with three access portals open and initial higher-grade underground ore being fed to the mill [3][4] Management Commentary - CEO Mark Brennan highlighted the significant potential of high-quality exploration targets and the decision to expand the drill program as a strategic move to enhance production and mine life [4] Company Overview - Cerrado Gold is a Toronto-based company focused on gold production, development, and exploration, owning the Minera Don Nicolas and Las Calandrias mines in Argentina, and holding interests in projects in Portugal and Canada [5][6][9]

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these conditions [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers this year [1]

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these challenges [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers [1]

Summary of Certara FY Conference Call - September 10, 2025 Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Health Technology and Biosimulation Key Points and Arguments Growth Strategy - Certara is focused on accelerating organic growth despite a subdued market environment, targeting mid-single-digit growth rates [4][5] - Investments in sales, marketing, and R&D are being made to enhance the commercial organization and software platforms [4][5] - New software enhancements, including Certara IQ (AI-enabled software for Quantitative Systems Pharmacology, QSP), are expected to drive growth [5][10] R&D and Product Development - Certara is addressing critical pain points in drug development, particularly the high failure rates of drug trials, by enhancing software capabilities [7] - The company has launched Certara Cloud, which has seen rapid adoption, particularly among large biopharma customers [11][12] - The tiered customer structure includes: - **Tier 1**: Large biopharma (50% of revenue) - **Tier 2**: Mid-sized companies (20% of revenue) - **Tier 3**: Biotechs (30% of revenue) [14][15] Market Dynamics - The funding environment for tier three customers remains challenging, but Certara has successfully targeted biotechs with funding potential [13][15] - The FDA's directive to shift away from animal testing is seen as a tailwind for Certara, enhancing customer discussions and driving demand for SIMCYP and QSP [24][34] Financial Performance - Certara expects an adjusted EBITDA margin of 30-32% for the year, consistent with previous performance [20] - The company is on track to meet its full-year plan despite some timing issues in software bookings for tier one customers [16][17] AI and Technology Integration - The acquisition of Vyasa has enabled Certara to integrate AI technology into its workflow and product offerings [25][26] - The co-author tool for regulatory writing has demonstrated a 40% efficiency improvement, appealing to regulatory customers [27] M&A and Strategic Review - Certara is actively engaged in a strategic review of its regulatory business, which has returned to growth with a 20-30% adjusted EBITDA margin [43][44] - The company is focused on software acquisitions to shift its revenue mix from services to software, aiming for a balanced profitability profile [45][46] Capital Allocation - Certara prioritizes R&D investments while also considering M&A opportunities and share buybacks, having authorized a $100 million share repurchase program [47][48] Additional Important Insights - Certara's longstanding relationship with the FDA provides a competitive advantage, as many FDA users are familiar with Certara's software [32][33] - The company is well-positioned to help biopharma clients find efficiencies across the drug development cycle, from discovery to submission [30][31] - The integration of Camaxon, a chem-informatics software company, is progressing well, with expectations to enhance margins and product offerings [40][41]